Related Experiment Video
Updated: May 26, 2026
08:30
Paradigms for Behavioral Assessment in Drosophila Model of Autism Spectrum Disorder
Published on: September 6, 2024
Pathways to drug development for autism spectrum disorders.
D R Hampson1, S Gholizadeh, L K K Pacey
1Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada. d.hampson@utoronto.ca
Clinical Pharmacology and Therapeutics
|December 30, 2011
Summary
New autism spectrum disorder (ASD) treatments may emerge from understanding fragile X syndrome (FXS) and Rett syndrome. Advances in neurochemistry and neuropathology offer hope for more effective ASD therapies.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Autism spectrum disorders (ASDs) are neurodevelopmental conditions with increasing prevalence.
- Current treatments for ASDs, fragile X syndrome (FXS), and Rett syndrome primarily manage symptoms, not underlying causes.
- Understanding the neurochemical basis of FXS has advanced its pharmacotherapy.
Purpose of the Study:
- To review recent advances in the biochemistry and neuropathology of ASDs, FXS, and Rett syndrome.
- To explore how knowledge from FXS and Rett syndrome research can inform ASD treatment development.
- To highlight potential pathways for novel and more effective ASD therapies.
Main Methods:
- Literature review of recent research on ASDs, FXS, and Rett syndrome.
- Analysis of neurochemical and neuropathological findings.
- Synthesis of knowledge transfer possibilities between related disorders.
Main Results:
- Significant progress in understanding FXS neurochemistry is leading to clinical trials.
- The neuropathophysiology of ASDs remains less understood compared to FXS.
- Potential applications of FXS and Rett syndrome insights to ASDs are identified.
Conclusions:
- Advances in understanding the neuropathology of related neurodevelopmental disorders offer promise for ASD treatment.
- Translational research from FXS and Rett syndrome may accelerate the development of effective ASD pharmacotherapies.
- Further investigation into the biochemistry and neuropathology of ASDs is crucial for therapeutic innovation.
Related Concept Videos
01:19Autism Spectrum Disorder
Autism spectrum disorder (ASD) is a neurodevelopmental condition marked by persistent deficits in social communication and interaction alongside restrictive and repetitive behaviors or interests. ASD is sometimes accompanied by intellectual impairment.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:26Modeling in Therapy
Modeling, a key technique in therapy, uses observational learning to help clients acquire and practice new skills by watching therapists demonstrate desired behaviors. This approach, rooted in Albert Bandura's concept of vicarious learning, plays a significant role in therapeutic interventions for various psychological conditions, including social anxiety, ADHD, and depression.
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in situations...
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in situations...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...